Abstract: The International Transporter Consortium (ITC) has recently described seven transporters of particular relevance to drug development. Based on the second ITC transporter workshop in 2012, we have identified additional transporters of emerging importance in pharmacokinetics, interference of drugs with transport of endogenous compounds, and drug-drug interactions (DDIs) in humans. The multidrug and toxin extrusion proteins (MATEs, gene symbol SLC47A) mediate excretion of organic cations into bile and urine. MATEs are important in renal DDIs. Multidrug resistance proteins (MRPs or ABCCs) are drug and conjugate efflux pumps, and impaired activity of MRP2 results in conjugated hyperbilirubinemia. The bile salt export pump (BSEP or ABCB11) prevents accumulation of toxic bile salt concentrations in hepatocytes, and BSEP inhibition or deficiency may cause cholestasis and liver injury. In addition, examples are presented on the roles of nucleoside and peptide transporters in drug targeting and disposition. This is a PDF file of an unedited peer-reviewed manuscript that has been accepted for publication. NPG is providing this early version of the manuscript as a service to our customers. The manuscript will undergo copyediting, typesetting and a proof review before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply. 
INTRODUCTION
Transporters are membrane bound proteins that control access of endogenous substances and xenobiotics (drugs) to various sites of the human body (1, 2) . In contrast to drug metabolizing enzymes, which are largely concentrated in the liver and intestine, transporters are present in all tissues in the body and play important roles in drug absorption, distribution, tissuespecific drug targeting, and elimination, thus influencing drug pharmacokinetics (PK) and pharmacodynamics (PD). Transporters can also work in concert with metabolizing enzymes in affecting a drug's PK and PD. Similar to metabolizing enzymes, transporters have substrate In addition to contributing to DDIs, transporters may contribute to drug tissue toxicity or serve as treatment targets. In March 2012, the ITC organized a second transporter workshop that included discussions of emerging transporters involved in DDIs, efficacy, and drug induced (8) . In addition, clinically important examples involving nucleoside transporters and peptide transporters were also presented (8) .
The goal of this whitepaper is to discuss the research and clinical observations available for emerging transporters of clinical importance. The clinical relevance and importance of these transporters and recommendations on how to study them during drug development and what criteria may be used to assess their role in DDIs and toxicity are discussed.
The emerging transporters MATE1 and MATE2K

General description
The multidrug and toxin extrusion proteins (MATEs) include three major functional solute carriers: MATE1 (SLC47A1), MATE2 (SLC47A2) and the splice variant MATE2K. The three functional isoforms are expressed abundantly in the apical membrane of the renal proximal tubule and play roles in the secretion of cations and zwitterions into urine (1, 9, 10 However, differences in ligand affinity between orthologs as well as general limitations of interpretation of rodent PK data (e.g., Cyp450 activity) need to be considered (Supplementary Table 2 ). NMEs be adopted and included along with OCT2 and OAT1/OAT3 (Figures 2 and 3) . The A c c e p t e d m a n u s c r i p t first decision tree, is targeted to NMEs for which renal secretion is an important route of drug elimination. For such compounds, in vitro uptake studies in MATE transfected cells are recommended. If the NME is found to be a substrate of MATEs (or OCT2), a clinical study is recommended to be considered with cimetidine or pyrimethamine as inhibitors. When evaluating the potential of a NME to cause a DDI due to inhibition of MATEs, the decision tree in Figure 3 , which is based on previously published ITC recommended cutoffs, suggests an empirical approach (4). That is, therapeutic maximum unbound concentrations of the NME that are greater than or equal to 1/10th of its in vitro IC 50 
Substrate and inhibitor selectivity
General description
Among the nine multidrug resistance proteins (MRPs) encoded in the human genome, MRP2 (ABCC2), MRP3 (ABCC3), and MRP4 (ABCC4) have received particular attention because of their roles in the disposition of drugs and conjugates (21) . MRPs are unidirectional, ATP-dependent efflux pumps in the plasma membrane of human cells and many other organisms (22) . Human MRP2, formerly also termed canalicular multispecific organic anion transporter (cMOAT), was the second member of the MRP subfamily to be identified by molecular cloning of its cDNA, and is localized to the apical membrane of hepatocytes, intestinal epithelia, and proximal tubules of the kidney (23 has a number of additional localizations important for drug elimination and action: it is localized to the apical (luminal) membrane of kidney proximal tubules and epithelia of the blood-brain barrier (24) and to membranes of blood platelets (25) .
Structure and function
Human MRP2 is an integral plasma membrane glycoprotein composed of 1,545 amino acids. The total number of amino acids for MRP3 and MRP4 is 1,527 and 1,325, respectively, and the amino acid identities of MRP2 compared to MRP3 and MRP4 are 48% and 39%, respectively (22, 23) . All MRPs contain two ATP-binding domains. The ABCC genes encoding the MRP transport proteins considered here are located on different chromosomes, namely 10q24 for MRP2, 17q22 for MRP3, and 13q32 for MRP4 (22, 23) . At present, MRP2 orthologs have been cloned from more than 20 organisms, ranging from cellular slime molds, plants, bony fishes, and birds to many mammalian species, including human, rat, mouse, dog, rabbit, and monkey.
Thus, MRP2 is a phylogenetically ancient efflux pump involved in detoxification. Subsequently, bilirubin glucuronides can be eliminated via the kidneys into urine. In intestinal epithelia, basolateral MRP3 may also function in transport of glucuronides, formed intracellularly, into blood. Detailed studies in knock-out mice lacking Mrp3 support the role of this basolateral efflux pump in the transport of bilirubin glucuronides from cells into blood (27) .
The substrate specificity of MRP4 is relatively broad compared to other MRP subfamily members (21, 24, 28) . This is due in part to the broadening of the substrate spectrum in the presence of GSH, which is normally present in living cells at millimolar concentrations, as exemplified by the MRP4-mediated ATP-dependent transport of bile acids (28) OATP1B1, OATP1B3, and OATP2B1 (29) . Cyclosporin A acts as a good but nonselective inhibitor of MRP2, in addition to its more potent inhibition of MDR1, BSEP (30) , and the uptake transporters OATP1B1 and OATP1B3 (29) . Corresponding inhibitory actions on uptake as well as efflux have been described for rifampicin and rifamycin SV. Thus, for studies in vivo and with intact cells, the lack of selectivity with respect to MRP subfamily members as well as the action of the inhibitors on uptake transporters must be considered.
Genetic variants
A large number of genetic variants in the ABCC2 gene encoding MRP2 have been identified in various ethnic groups, but only some of these variants lead to loss of the MRP2 protein or to loss of functionally active MRP2 in apical plasma membranes (23) . A complete loss of functionally active MRP2 in the hepatocyte canalicular membrane has been recognized as the molecular basis of Dubin-Johnson syndrome (31) , which is associated with mild, predominantly conjugated hyperbilirubinemia, and upregulation of basolateral MRP3 in human hepatocytes and Mrp3 in Mrp2-deficient rats (21) . Under this condition, MRP3/Mrp3 compensate for the impairment of MRP2/Mrp2 function by efflux into blood of conjugated bilirubin and other endogenous and xenobiotic anionic substrates of MRP2 and MRP3.
Multiple genetic polymorphisms exist in the ABCC3 gene (32) . However, so far no major PK consequences have been documented. The ABCC4 gene is highly polymorphic, and large variability of ABCC4/MRP4 mRNA (38-fold) and protein (45-fold) expression was found in human liver, and significant upregulation was observed in livers of patients with cholestasis (33) .
A common single-nucleotide polymorphism (rs3765534; >18% in the Japanese population), A c c e p t e d m a n u s c r i p t which reduces MRP4 function, seems to be associated with thiopurine-induced hematopoietic toxicity (34) .
Methodology for evaluating function
The exact substrate specificity of the ATP-dependent efflux pumps of the MRP subfamily, MRP2, MRP3, and MRP4, may be defined in inside-out-oriented membrane vesicles for which substrate concentrations can be adjusted and metabolism or complex formation, as it may occur in intact cells and in vivo, can be controlled. Moreover, 
A c c e p t e d m a n u s c r i p t ACCEPTED ARTICLE PREVIEW
For a NME, it is important to examine MRP2 inhibition if drug-induced conjugated hyperbilirubinemia is observed in patients or in preclinical species. To date no classical PK DDI has been attributed to MRP2 and there is no evidence that MRP3 or MRP4 should be examined or that there is a likelihood of DDIs or toxicity due to being a substrate of MRP2. It is plausible, but not proven, that hepatotoxicity may result, however, from compounds or metabolites that potently inhibit MRP2 as well as MRP3 and MRP4 and thus cannot exit from hepatocytes via alternative pathways.
The bile salt export pump (BSEP) and its role in hepatotoxicity
General Description
In addition to elimination of drugs and xenobiotics, bile formation is another key function of the liver. Bile has two major physiologic functions: it provides a vehicle for excretion of poorly water soluble substances (e.g., cholesterol) and is essential for digestion and absorption of fat and fat soluble vitamins in the intestine. Bile is mainly composed of small ions, organic anions, lipids (e.g., phosphatidylcholine) and bile salts (36) . Bile salts are amphipathic molecules, have detergent properties and are highly concentrated in bile (36) where they form mixed micelles with phospholipids, which act as carriers for poorly water soluble substances (36) . Due to their detergent properties, bile salts can be highly toxic to hepatocytes if they accumulate intracellularly (37).
Bile salts are taken up from the sinusoidal blood plasma by several transporters into hepatocytes (38) , where they mix with newly synthesized bile salts. Bile salts are secreted by the species. In addition to bile salts, pravastatin has been reported to be a BSEP substrate, albeit with low affinity (40) , and indirect evidence from sandwich-cultured hepatocytes suggests that the antifungal micafungin may be transported by BSEP (43) . Taking together the evidence obtained so far, it seems unlikely that BSEP plays a major role in drug export from hepatocytes into bile and consequently in drug disposition.
Genetic variants
Much has been learned about the physiologic role of BSEP from patients with inherited liver diseases due to impaired BSEP function. If a NME inhibits BSEP with a low K i value, additional experiments may be warranted. One additional test system for a NME is human hepatocytes cultured in a sandwich configuration (53) . This system offers the advantage that it is metabolically competent and to some extent includes the potential impact of metabolites on BSEP. In addition, experiments in a preclinical species, e.g. rats, may be warranted. If the NME is also an inhibitor of rat Bsep, application of the NME in a repeat dose study for several weeks to animals at a dose leading to at least the expected human serum concentrations will be helpful. It is recommended that this test includes sampling of serum on a daily basis followed by measurements of bile salt concentration, alkaline phosphatase, and transaminases. A course of 
Clinical significance and drug development recommendations
The decision whether or not to investigate a NME for BSEP interaction may depend on various factors. As BSEP is an unlikely player in disposition of NMEs, concerns may focus on potential DILI related to BSEP. Here, inhibition of BSEP will lead to intracellular accumulation of bile salts followed by cytotoxic events.
Currently, it is impossible to define a value for a BSEP inhibition constant that will realistically predict significant BSEP-mediated DILI. The reasons are: 1) While a trend between low IC 50 values of BSEP inhibition and DILI was described (48, 49) , no correlation between C max, unbound with the potency of BSEP inhibition and with DILI was observed (48) , showing that the uptake mechanism of drugs into hepatocytes is a major contributor to intracellular drug concentrations. At present, the exact transport mechanism and in particular the energetics of the OATPs, which are the major drug uptake systems into hepatocytes, are poorly understood. It should also be noted that cyclosporin A is a very potent BSEP inhibitor although it is widely used in solid organ transplantation despite the occurrence of cholestatic episodes. In addition,
there is large interindividual variability of BSEP protein levels in normal human liver 
Other Transporters of Clinical Importance
The transporters described above and in the previous ITC white paper have the potential to interact with a broad range of drugs. However, it is important to keep in mind that for certain classes of drugs other transport mechanisms may be important. Two such examples are given below: Human equilibrative nucleoside transporter 1 (hENT1) which is important in the delivery hENT1 and hENT2 both transport a wide range of purine and pyrimidine nucleosides, and hENT1 has higher apparent affinities for its substrates than hENT2. Both also have the capacity to transport nucleobases (hENT2 > hENT1), although the physiological importance of these activities is unknown (56, 57) . In general, nucleoside analog drugs are poorer substrates for hENT1 and hENT2 than their physiological counterparts. Among clinical anticancer nucleosides, fludarabine, cladribine, clofarabine, 5-fluorouridine, 2'-deoxy-5-fluorouridine, azacytidine and decitabine are substrates of both, whereas gemcitabine and cytarabine are preferred by hENT1.
Among clinical antiviral nucleosides, hENT2 appears to be more important than hENT1 in cellular uptake of zidovudine, zalcitabine and didanosine.
Transport assays
Because most human cell types contain multiple hNT types, the most reliable functional studies of hNTs are those conducted with (i) recombinant proteins produced individually in NT activity), oocytes of Xenopus laevis (lack endogenous NT activity) and human cell lines (mutants that lack NT activity) and (ii) native proteins in cells that either produce a single transporter type (e.g., hENT1-containing human erythrocytes) or that can be manipulated pharmacologically by treatment with selective NT inhibitors such that only a single transporter type is functional (e.g., treatment of hENT1/2-containing cells with NBMPR). For methodological details see (58, 59) . Studies of radioisotope fluxes can be undertaken with these systems to identify substrates and inhibitors, which for some hNT and cell combinations is difficult because of rapid equilibration of intra and extracellular nucleosides.
Clinical implications: hENT1 in anticancer therapies with nucleoside drugs
Although the potential role of hENT1 in the clinical activity of nucleoside drugs has been recognized for decades (reviewed in (60)), evidence of its importance has only recently been obtained. The development of monoclonal antibodies against hENT1 (61) provided the tools for analysis of the distribution of hENT1 in human tissues, including immunohistochemistry studies of human cancer samples, which revealed marked variations in its abundance in a variety of cancers, giving rise to the hypothesis that low levels of hENT1 in target tumors predicts resistance to nucleoside drugs. In a retrospective study of pancreatic adenocarcinoma samples from deceased patients who received gemcitabine mono-chemotherapy for palliation, patients whose tumor cells all exhibited hENT1 immunostaining had longer survival times than those whose tumors contained cells that lacked hENT1 immunostaining (13 vs 4 months), indicating a relationship between hENT1 abundance and response to gemcitabine (62) . A subsequent study of hENT1 abundance and gemcitabine therapy in a larger group of pancreatic adenocarcinoma 
Peptide transport
Another class of transporter that will handle selected targeted drugs is the Peptide Transporter Family (gene symbol SLC15) (64) . There are four transporters in the SLC15 family antibiotics, ACE and renin inhibitors) and in peptide prodrugs (valacyclovir) (65) . PEPT1 is apically located in the intestine and to a lesser extent in the kidney. PEPT1 is responsible for the uptake of di-and tri-peptides from the intestinal lumen into the blood and in the kidney for the scavenging of peptides from the urine back into the renal proximal tubule cells. PEPT2 is located in the kidney, but is also found at the blood cerebrospinal fluid barrier and the lung.
PEPT2 is the primary mechanism in the proximal tubule cells for the reabsorption of di-and tri-A c c e p t e d m a n u s c r i p t peptides from the urine. In the brain, PEPT2 is used to clear di-and tri-peptides from the cerebrospinal fluid (CSF) back into the blood and in the lung PEPT2 absorbs peptides.
Because of PEPT1's location and absorptive function in the intestine, it is a useful mechanism to increase the bioavailability of small, hydrophilic, charged molecules (64) . It has been utilized to increase the bioavailability of amino acid-and nucleoside-like drugs. It is also known to transport some antibiotics. It transports molecules via a proton dependent mechanism taking advantage of the acidic micro-environment of the intestine to co-transport a substrate along with a proton (65) . PEPT1 is considered a low affinity high capacity transporter. The affinity (K m ) for natural substrates is in the high micromolar range and for drugs such as beta lactam antibiotics the K m values are in the low millimolar range. However, since it has high capacity and is expressed along the length of the gut, it efficiently scavenges its substrates' uptake into intestinal enterococytes where they are eventually shunted into the blood.
The genetics of PEPT1 have been studied in vitro and the most frequent coding region SNP (S117N) does not lead to functional change in vitro (66) . Two SNPs that do lead to functional changes in vitro (P586L and F28Y) have very low frequency in all populations studied to date (65) . To date no clinical consequences for any PEPT1 variants have been found.
Functional studies for PEPT1 have been carried out in a number of heterologous expression systems. The transporter is easily expressed transiently in mammalian cell lines such as HEK, COS or HeLa or it can also be stably expressed (64) . Many laboratories have also used oocyte expression to study peptide transport. PEPT1 is also expressed in intestinal cell lines A c c e p t e d m a n u s c r i p t such as CACO-2. However, the expression level is low and requires 14 to 21 days in culture for maximal expression. The role of PEPT1 in absorption can also be studied in knockout mice (67) .
Although the knock-out strains have been characterized and used to study probe substrates, they are not currently commercially available.
Clinical significance and drug development recommendations
PEPT1 works well as a mechanism for oral delivery of small charged amino acid, peptide or nucleoside like drugs (65) . The transporter appears not to be easily saturated and can deliver relatively large doses of drugs. For example, the cephalosporin antibiotics are given at gram doses. Review of labels for drugs (e.g., cephalosporins, valacyclovir, enalapril) that utilize peptide transporters for absorption shows little concern for interactions during absorption as there are no consistent food interactions or interactions with other drugs transported by PEPT1.
It is of note that PEPT1 appears to be upregulated in inflammatory bowel disease leading to expression of PEPT1 in the colon which is believed to be part of the proinflammatory response (68) . Thus, although PEPT1 is normally thought of as a delivery mechanism, it may also be a pharmacological target for inflammatory bowel disease. There have also been studies as to its role in various cancers as a possible delivery mechanism (64, 65) .
SUMMARY AND FUTURE PERSPECTIVES
Membrane transporters of emerging importance in pharmacokinetics, drug-drug interactions, and interference of drugs with the transport of endogenous compounds are discussed in this paper. We focus here on human transporters involved in the uptake and efflux 
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Figure-3: Decision tree for renal transporter inhibitors proposed by ITC a-First step might be uptake of model substrate decreases with increasing concentration of NME, then full IC 50 curve (modified from Ref 6) . b-For NME that is a MATE1, MATE2K or OCT2 inhibitor, metformin may be used as the substrate for the clinical drug interaction study.
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